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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 51, Revision 1 
(FGE.51Rev1): 
Consideration of alicyclic ketones and secondary alcohols and related esters 
evaluated by the JECFA (59
th
 meeting) structurally related to alicyclic 
ketones secondary alcohols and related esters in FGE.09Rev3 (2011)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to consider evaluations of flavouring substances assessed since 
2000 by the Joint FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide 
whether further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000. 
The present consideration concerns a group of 20 alicyclic ketones and secondary alcohols and related 
esters evaluated by JECFA (59th meeting) in 2002. This revision is made due to inclusion of seven 
additional substances cleared for genotoxicity concern compared to the previous version. The 
substances were evaluated through a stepwise approach that integrates information on structure-
activity relationships, intake from current uses, toxicological threshold of concern, and available data 
on metabolism and toxicity. The Panel agrees with the application of the Procedure as performed by 
the JECFA for all 20 substances considered in this FGE and agrees with the JECFA conclusion, “No 
safety concern at estimated levels of intake as flavouring substances” based on the MSDI approach. 
Besides the safety assessment of these flavouring substances, the specifications for the materials of 
commerce have also been considered and for all 20 substances, the information is adequate. 
 
© European Food Safety Authority, 2012 
                                                     
1 On request from the European Commission, Question No (EFSA-Q-2011-01040; EFSA-Q-2011-01041; EFSA-Q-2011- 
01042; EFSA-Q-2011-01043; EFSA-Q-2011-01044; EFSA-Q-2011-01045; EFSA-Q-2011-01046), adopted on 22 March 
2012. 
2  Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Leon Brimer, Laurence Castle, Karl-Heinz Engel, Roland 
Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean Claude Lhuguenot, 
Wim Mennes, Maria Rosaria Milana, Iona Pratt, Kettil Svensson, Fidel Toldra, Detlef Wölfle. Correspondence: 
cef@efsa.europa.eu. 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Flavourings for the preparation of 
this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Leon Brimer, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, 
Henrik Frandsen, Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard 
Mulder, Karin Nørby, Gerrit Speijers, Harriet Wallin and EFSA‟s staff member Kim Rygaard Nielsen for the preparatory 
work on this scientific Opinion. 
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SUMMARY 
The Scientific Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) was asked to give scientific advice to the Commission on the implications for human health of 
chemically defined flavouring substances used in or on foodstuffs in the Member States. In particular, 
the Panel was requested to consider the Joint FAO/WHO Expert Committee on Food Additives (the 
JECFA) evaluations of flavouring substances assessed since 2000, and to decide whether no further 
evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000. These 
flavouring substances are listed in the Register, which was adopted by Commission Decision 
1999/217/EC and its consecutive amendments. 
This revision of FGE.51 is made due to the consideration of the seven the alpha,beta-unsaturated 
substances [FL-no: 07.034, 07.035, 07.098, 07.126, 07.129, 07.172 and 09.930] compared to the 
previous version of FGE.51. Furthermore, EU production volume on one substance [FL-no: 09.230] 
and data on stereoisomerism for four substances [FL-no: 02.209, 07.045, 07.095 and 07.257] have 
been provided since the publication of FGE.51. 
The JECFA has evaluated a group of 25 flavouring substances consisting of alicyclic ketones, 
secondary alcohols and related esters at its 59
th
 meeting. Two of the JECFA-evaluated substances are 
not in the Register (4-methyl cyclohexanone (JECFA no: 1104) and (E)-2-(2-octenyl) cyclopentanone 
(JECFA no: 1116)) and ten of the substances are alpha,beta-unsaturated ketones or precursors for 
such, which is recognized as a structural alert for genotoxicity. Seven of these 10 alpha,beta-
unsaturated substances [FL-no: 07.034, 07.035, 07.098, 07.126, 07.129, 07.172 and 09.930] have been 
evaluated with respect to their genotoxic potential in FGE.211 (EFSA, 2011e) or in FGE.212Rev1 
(EFSA, 2011f), and the Panel concluded that the data available ruled out the concern for genotoxicity 
and accordingly these seven substances can be evaluated through the Procedure. 
The present consideration therefore concerns 20 alicyclic ketones, secondary alcohols and related 
esters evaluated by the JECFA at its 59
th
 meeting and will be considered in relation to the European 
Food Safety Authority (EFSA) evaluation of 17 secondary alicyclic saturated and unsaturated 
alcohols, ketones and esters containing secondary alicyclic alcohols evaluated in the Flavouring 
Group Evaluation 09, Revision 3 (FGE.09Rev3). 
The Panel agrees with the application of the Procedure as performed by the JECFA for the 20 
substances considered in this FGE. 
For all substances evaluated through the Procedure use levels are needed to calculate the mTAMDIs 
in order to identify those flavouring substances that need more refined exposure assessment and to 
finalise the evaluation. 
In order to determine whether the conclusion for the JECFA-evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity tests are available for all 20 substances 
evaluated in this FGE.51Rev1. 
For all 20 evaluated alicyclic ketones, secondary alcohols and related esters [FL-no: 02.209 07.034, 
07.035, 07.045, 07.095, 07.098, 07.126, 07.129, 07.148, 07.149, 07.172, 07.179, 07.180, 07.257, 
09.027, 09.140, 09.160, 09.230, 09.464 and 09.930], the Panel agrees with the JECFA conclusion, 
“No safety concern at estimated levels of intake as flavouring substance” based on the MSDI 
approach. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a).  
Commission Regulation (EC) No 1565/2000 lays down that substances that are contained in the 
Register and will be classified in the future by the Joint FAO/WHO Expert Committee on Food 
Additives (the JECFA) so as to present no safety concern at current levels of intake will be considered 
by the European Food Safety Authority (EFSA), who may then decide that no further evaluation is 
necessary. 
















 meetings, the JECFA 
evaluated about 1000 substances, which are in the EU Register. 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to consider the JECFA evaluations of 
flavouring substances assessed since 2000, and to decide whether no further evaluation is necessary, as 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a). These flavouring substances 
are listed in the Register which was adopted by Commission Decision 1999/217 EC (EC, 1999a) and 
its consecutive amendments. 
The evaluation programme was finalised at the end of 2009. 
After the finalisation of the evaluation programme, in their letters of the 7
th
 May 2010 and 3
rd
 June 
2010, the Commission requested EFSA to carry out re-evaluation of the flavouring substances, 
tetramethyl ethylcyclohexenone [FL-no: 07.035], 3-methylcyclohex-2-en-1-one [FL-no: 07.098], 
3,5,5-trimethylcyclohex-2-en-1-one (isophorone) [FL-no: 07.126], 3-methyl-5-propylcyclohex-2-en-1-
one [FL-no: 07.129],  4-isopropylcyclohex-2-en-1-one [FL-no: 07.172], 2-hexylidenecyclopentan-1-
one [FL-no: 07.034] and 1(7),8-p-menthadien-2-yl acetate (mixture of (E) and (Z) isomers) [FL-no: 
09.930] based on additionally submitted data on genotoxicity, and depending on the outcome, to 
proceed to the evaluation of these flavouring substances through the Procedure, also according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). 
ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), hereafter named the “EFSA Procedure”. 
This Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999a), which has 
been derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b), hereafter named the 
“JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
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substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65
th
 meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006c). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram/person/day as part of the evaluation 
Procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per 
person per day would not be expected to present a safety concern. The Committee recommended that 
the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be 
amended to include the last step on the right-hand side of the original procedure (“Do the condition of 
use result in an intake greater than 1.5 microgram per day?”)” (JECFA, 1999b).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 microgram per person per day. 
Flavouring Group Evaluation 51, Revision 1 
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Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999a), the Panel has in its evaluation focussed on a 
possible genotoxic potential of the flavouring substances or of structurally related substances. 
Generally, substances for which the Panel has concluded that there is an indication of genotoxic 
potential in vitro, will not be evaluated using the EFSA Procedure until further genotoxicity data are 
provided. Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated 
through the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE 
At its 59
th
 meeting the JECFA evaluated a group of 25 flavouring substances consisting of alicyclic 
ketones, secondary alcohols and related esters. Two substances were not in the Register, and 10 are 
alpha,beta-unsaturated ketones or precursors for such which have been considered together with other 
alpha,beta-unsaturated substances. The remaining 13 flavouring substances have originally been 
considered by EFSA in the FGE.51 (EFSA, 2008aj). 
FGE Opinion adopted 
by EFSA 
Link No. of candidate 
substances 
FGE.51 16 May 2007 http://www.efsa.europa.eu/en/efsajournal/doc/855.pdf 13 
FGE.51Rev1 22 March 2012  20 
 
The present revision of FGE.51, FGE.51Rev1, includes the consideration of seven additional 
substances [FL-no: 07.034, 07.035, 07.098, 07.126, 07.129, 07.172 and 09.930]. 
Six of the seven additional substances [FL-no: 07.034, 07.035, 07.098, 07.126, 07.129 and 07.172] are 
alpha,beta-unsaturated ketones originally allocated to FGE.211 (EFSA, 2011e) and FGE.212 (EFSA, 
2009ai). The seventh substance [FL-no: 09.930] is a precursor for such ketones originally allocated to 
FGE.211. The seven substances have been considered with respect to genotoxicity and the Panel 
concluded in FGE.211 (EFSA, 2011e) and FGE.212Rev1 (EFSA, 2011f)) that the data available ruled 
out the concern for genotoxicity and accordingly the substances can be evaluated through the 
Procedure in this FGE.51Rev1. The information concerning genotoxicity of these seven substances is 
described in Section 3.3 and 3.4. 
Since the publication of FGE.51, the EU production volume has been provided for the substance, [FL-
no: 09.230] for which the evaluation could not be finalised in the previous version of this FGE, due to 
lack of these data. Based on the newly submitted EU production volume, the substance has already 
been evaluated in FGE.96
4
 (EFSA, 2010al), but for the sake of completion, the information has also 
been included here as well. 
                                                     
4
 Consideration of 88 flavouring substances considered by EFSA for which EU production volumes / anticipated production volumes have been submitted on 
request by DG SANCO. 
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Finally, new information on the stereoisomeric composition has been provided for four substances 
[FL-no: 02.209, 07.045, 07.095 and 07.257] since the previous version of FGE.51 (EFFA, 2010a). 
A search in open literature for the seven new substances did not provide any further data on toxicity or 
metabolism. 
1. Presentation of the Substances in the JECFA Flavouring Group 
1.1. Description 
1.1.1. JECFA Status 
The JECFA has evaluated at its 59
th
 meeting a group of 25 flavouring substances consisting of 
alicyclic ketones, secondary alcohols and related esters (JECFA, 2002d; JECFA, 2003a).  
1.1.2. EFSA Considerations 
Two of the JECFA-evaluated substances are not in the Register (4-methyl cyclohexanone (JECFA no: 
1104) and (E)-2-(2-octenyl) cyclopentanone (JECFA no: 1116)). 
Seven of 10 alpha,beta-unsaturated ketones or precursors for such [FL-no: 07.034, 07.035, 07.098, 
07.126, 07.129, 07.172 and 09.930] have been considered with respect to genotoxicity in FGE.211 
(EFSA, 2011e) and FGE.212Rev1 (EFSA, 2011f), and the Panel concluded that the data available 
ruled out the concern for genotoxicity and accordingly the seven substances can be evaluated through 
the Procedure in this FGE. 
For the remaining three substances [FL-no: 07.033, 07.094 and 07.112] considered with respect to 
genotoxicity in FGE.212Rev1, a final conclusion of genotoxic properties could not be reached and 
additional data were requested. Accordingly, these three substance will not be considered in this FGE. 
This consideration will therefore deal with 20 JECFA-evaluated substances. 
The Panel concluded that the 20 substances in the JECFA flavouring group of alicyclic ketones, 
secondary alcohols and related esters are structurally related to the group of secondary alicyclic 
saturated and unsaturated alcohols, ketones and esters with secondary alicyclic alcohol moieties 
evaluated by EFSA in Flavouring Group Evaluation 09, Revision 3 (FGE.09Rev3) (EFSA, 2011x). 
1.2. Isomers 
1.2.1. Status 
Six of the substances have one chiral centre [FL-no: 07.045, 07.129, 07.172, 07.179, 07.180 and 
07.257] and four substances have two or more chiral centres [FL-no: 02.209, 07.035, 07.095 and 
09.930]. Two substances have possibility for cis/trans isomerism [FL-no: 07.034 and 07.257]. 
1.2.2. EFSA Considerations 
Adequate information on isomeric composition is available for all substances. 
1.3. Specifications 
1.3.1. JECFA Status 
The JECFA specifications are available for all the 20 substances (JECFA, 2002d). See Table 1. 
1.3.2. EFSA Considerations 
The available specifications are considered adequate for all the substances (See Section 1.2). 
Flavouring Group Evaluation 51, Revision 1 
 
 
EFSA Journal 2012;10(4):2636 9 
2. Intake Estimations 
2.1. JECFA Status 
For all the substances evaluated through the JECFA Procedure, intake data are available for the EU, 
see Table 3.1.  
2.2.  EFSA Considerations 
Tonnage data are available for the EU allowing calculation of the intake estimates (MSDI). The Panel 
noted that since no use levels were submitted no mTAMDI values can be calculated.  
3. Genotoxicity Data 
3.1. Genotoxicity Studies – Text Taken5 from the JECFA (JECFA, 2003a) 
In vitro 
Eight of the 13
6
 alicyclic ketones, secondary alcohols and related esters have been tested for 
genotoxicity. Overall, negative results were reported in the standard assay for reverse mutation when 
various strains of Salmonella typhimurium (TA98, TA100, TA1535, TA1537 and TA1538) were 
incubated with up to 10000 microgram/plate of cyclohexanone [FL-no: 07.148]) or isophorone [FL-
no: 07.126], 2.5 - 2500 µg/plate of cyclopentanone [FL-no: 07.149], up to 4200 µg/plate of 2,2,6-
trimethylcyclohexanone [FL-no: 07.045] or up to 3600 µg/plate of 2-hexylidenecyclopentan-1-one 
[FL-no: 07.034] or tetramethyl ethylcyclohexanone [FL-no: 07.035],  with or without metabolic 
activation (Florin et al., 1980; Haworth et al., 1983; Wild et al., 1983; Mortelmans et al., 1986). In 
another test for reverse mutation with S. typhimurium TA98, TA100, TA1535 and TA1537 (only an 
abstract), cyclohexanone was reported to produce „a large number of revertants‟ in TA98, with no 
further elaboration and no results for the other strains. The concentrations and test conditions used 
were not specified (Massoud et al., 1980).  
Both cyclohexyl acetate [FL-no: 09.027] and cyclohexyl butyrate [FL-no: 09.230] gave negative 
results for mutation in Bacillus subtilis M45 (rec
–
) and H17 (rec
+
) (Oda et al., 1979; Yoo, 1986). 
Positive results were reported with cyclohexanone in an assay for forward mutation assay in B. subtilis 
(Massoud et al., 1980); however, as previously stated, no concentrations or test conditions were 
reported in the abstract. 
The results for forward mutation in mouse lymphoma cells were generally negative with 
isophorone, with or without metabolic activation (NTP, 1986d; McKee et al., 1987; 
O‟Donoghue et al., 1988). An increased mutation frequency was reported in L5178Y Tk+/- 
mouse lymphoma cells without metabolic activation at concentrations of 400 and 800 µg/ml. 
Isophorone was lethal at 1600 µg/ml (MacGregor et al., 1988a). 
Cyclohexanone [FL-no: 07.148] at concentrations up to 980 microgram/ml induced chromosomal 
aberrations in human lymphocytes with or without metabolic activation (Collin, 1971; Lederer et al., 
1971; Dyshlovoi et al., 1981). It did not induce chromosomal aberrations in Chinese hamster ovary 
cells at a concentration of 7.5 µl/ml, with or without metabolic activation (Aaron et al., 1985). 
Isophorone [FL-no: 07.126] gave equivocal results in Chinese hamster ovary cells. In one study, no 
chromosomal aberrations were induced with or without metabolic activation at concentrations up to 
1600 µg/ml (Gulati et al., 1989), whereas in another study isophorone at a concentration of 1200 
µg/ml without metabolic activation or at a concentration of 1500 µg/ml with metabolic activation 
induced chromosomal aberrations (Matsuoka et al., 1996); however, lower concentrations of 250 -
1000 µg/ml tested without metabolic activation did not. In an assay for sister chromatid exchange, 
                                                     
5
 The text is taken verbatim from the indicated reference source, but text related to substances not included in FGE.51 has been removed. 
6
 The genotoxicity data available for the seven new substances are summarised in Sections 3.3. and 3.4. 
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cyclohexanone at a concentration of 7.5 µl/ml gave weakly positive results in Chinese hamster ovary 
cells in the absence of metabolic activation and negative results in the presence of metabolic activation 
(Aaron et al., 1985). Similarly, isophorone induced sister chromatid exchange in Chinese hamster 
ovary cells only when tested without metabolic activation at concentrations of 500 - 1000 µg/ml and 
then only after delayed harvesting due to the cytostatic effect of isophorone (Gulati et al., 1989). At 
lower concentrations tested without metabolic activation or at concentrations up to 1600 µg/mL tested 
with metabolic activation, isophorone did not induce sister chromatid exchange (NTP, 1986d; Gulati 
et al., 1989). In an assay for unscheduled DNA synthesis in rat hepatocytes, isophorone showed no 
sign of genotoxicity at concentrations up to 200 µl/ml (McKee et al., 1987; O‟Donoghue et al., 1988). 
In vivo 
When cyclohexanone [FL-no: 07.148], 2-hexylidenecyclopentan-1-one [FL-no: 07.034], tetramethyl 
ethylcyclohexanone [FL-no: 07.035] or isophorone [FL-no: 07.126] was fed to adult Drosophila 
melanogaster for 3 days, no mutations were observed (Goncharova, 1970; Wild et al., 1983; Foureman 
et al., 1994). In addition, negative results were obtained when D. melanogaster were injected with a 
single dose of 12 500 µg of isophorone (Foureman et al., 1994).  
There was no increase in the frequency of micronucleated polychromatic erythrocytes in the 
bone marrow of male or female CD-1 mice given isophorone  [FL-no: 07.126] at a dose of 
540 µg/kg bw by intraperitoneal injection (McKee et al., 1987; O‟Donoghue et al., 1988) or in 
NMRI mice injected intraperitoneally with 2-hexylidenecyclopentan-1-one at a dose of 170, 
330 or 500 mg/kg bw or tetramethyl ethylcyclopentenone at a dose of 180, 310 or 450 mg/kg 
bw (Wild et al., 1983). 
Conclusion on genotoxicity 
Cyclohexyl acetate [FL-no: 09.027], cyclohexyl butyrate [FL-no: 09.230], cyclopentanone [FL-no: 
07.149], 2,2,6-trimethyl cyclohexanone [FL-no: 07.045] and tetramethyl ethylcyclohexanone (mixed 
isomers) [FL-no: 07.035], gave negative results in assays for genotoxicity in vitro. The results reported 
for the genotoxicity of cyclohexanone [FL-no: 07.148] and isophorone [FL-no: 07.126] are 
conflicting. Most of the assays were conducted before 1986, when the pH and ionic strength of test 
media were often not adequately maintained. Mammalian cells in situ rely on complex regulatory 
mechanisms to maintain homeostatic conditions, and those in culture are not equipped to respond to 
environmental changes; therefore, it is important that the culture media used in mammalian cell assays 
be maintained at a pH of approximately 6.8 - 7.5. A lower pH or changes in osmolality due to the test 
agents can give rise to false-positive results, especially when metabolic activation systems are added. 
Acidity facilitates the breakdown of the components of such systems into mutagenic agents (Brusick, 
1986). 
The equivocal results of the assays for genotoxicity with cyclohexanone in vitro can be interpreted in 
terms of physiochemical properties. Compounds that are structurally similar to cyclohexanone have 
excellent membrane permeability and hydrogen bonding potential (Slater, 1963; Slater, 1967; 
Moreland, 1994). When cyclohexanone and related substances are tested in vitro, they may induce 
membrane expansion, leading to multiple effects on membrane-related processes. Membrane 
expansion may increase cell volume and lipid storage vacuoles, block ionic conductance channels, 
limit the availability of ATP and alter ion fluxes and metabolite distribution between the cytoplasm 
and organelles. Given these physiochemical properties, it is highly unlikely that any consistent pattern 
of genotoxicity would result from a battery of assays in bacterial and mammalian cells. 
Overall, the tests for genotoxicity yielded mainly negative results. Positive results were reported in 
mammalian cells at cytotoxic concentrations, usually in the absence of biotransformation enzymes. 
The results of assays in vivo were negative. 
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For a summary of in vitro / in vivo genotoxicity data considered by the JECFA, see Table 2.1. Some of 
the studies, however, have only been summarised in Tables 2.5 - 2.6. 
3.2. Genotoxicity Studies - Text Taken7 from EFSA FGE.09Rev3 (EFSA, 2011x) 
In vitro / in vivo 
Genoxicity data are available for only three candidate substances cyclohexanol [FL-no: 02.070], 
cyclopentanol [FL-no: 02.135], methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520] and for 
nine supporting substances and one structurally related substances.  
Cyclohexanol FL-no: 02.070  was not genotoxic in two Ames tests and in an in vivo micronucleus 
assay, which are all considered as valid studies. However, the results of the in vivo study are of limited 
relevance, due to the lack of evidence that the substance did reach the bone marrow. Inconclusive 
results were reported in an in vitro chromosomal aberration assay with human leukocytes and negative 
results were reported in a dominant lethal mutations assay with Drosophila melanogaster; both studies 
were considered inadequate. Cyclopentanol FL-no: 02.135  was studied in a valid Ames test. No 
mutagenicity was found. 
A battery of in vitro and in vivo genotoxicity studies were conducted on methyl 3-oxo-2-pentyl-1-
cyclopentylacetate [FL-no: 09.520] including valid negative reverse mutation tests in Escherichia coli 
(Wagner and Klug, 2000) and Salmonella typhimurium (Thompson, 2000). 
In a mouse lymphoma test, pre-dating GLP, a more than 2-fold increase of the mutant frequency over 
the solvent treated control values was found at the highest tested cytotoxic concentration of 300 µg/ml 
in the presence of metabolic activation, and at the two highest tested cytotoxic concentrations of 200 
and 300 µg/ml, in the absence of metabolic activation. Only limited documentation is provided in the 
study report; together with the fact that several cultures were infected and a lack of a confirmatory test, 
it is impossible to assess the reliability of these results (Ross and Harris, 1979b).  
No induction of forward mutations at the TK locus in L5178Y mouse lymphoma cells were found in a 
study performed in compliance with the current OECD test guidelines, both in the absence and in the 
presence of metabolic activation, up to and including cytotoxic concentrations (Cifone, 2001).  
Methyl 3-oxo-2-pentyl-1-cyclopentylacetate was tested in a bone marrow micronucleus test in mice 
following a single intraperitoneal administration of 0, 280, 560 or 1120 mg/kg bw in corn oil. The 
study was performed in compliance with the current OECD test guidelines. The two highest doses 
chosen induced clear signs of toxicity; slight reductions (up to 12 %) in the ratio of polychromatic 
erythrocytes to total erythrocytes were found, indicating that the test material had reached the target 
cells. No increase in micronucleated cells was found in the groups treated with the test material. The 
positive control induced the expected increases (Gudi and Krsmanovic, 1998). 
In an Unscheduled DNA Synthesis (UDS) study, the ability of methyl 3-oxo-2-pentyl-1-
cyclopentylacetate to induce DNA repair was studied in isolated rat hepatocytes after administration in 
vivo. The study was performed in compliance with the current OECD Guideline 486 (OECD, 1997). 
Methyl 3-oxo-2-pentyl-1-cyclopentylacetate was administered to male Sprague-Dawley CD rats by 
intra-peritoneal injection in doses of 333.3 and 1000 mg/kg bw (the latter dose was the maximum 
tolerated dose) followed by liver perfusion at 2 or 16 hours after dosing. No marked increase in the 
incidence of UDS was observed at either dose level or perfusion time. Statistically significant 
differences were revealed in the positive control groups when compared to the negative control group 
and the test article (Durward, 2001). 
Genotoxicity data are available for nine supporting substances [FL-no: 02.015, 02.062, 07.148, 
07.176, 09.027, 09.215, 09.230, 07.149 and 07.045]. 
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Cyclohexanone FL-no: 07.148 , structurally related to the alicyclic ketones and secondary alcohols in 
this FGE, was not mutagenic in an Ames test, considered to be valid. Negative and positive results 
were reported in several other in vitro studies at gene and chromosomal level, as well as a negative 
result in a sex-linked recessive lethal mutations in D. melanogaster. However, these studies were 
considered inadequate.  
Menthol FL-no: 02.015  gave negative results in an in vitro alkaline elution assay for detecting DNA 
single strand breaks in rat hepatocytes. With the same substance equivocal results in an in vivo host 
mediated mutation assay were observed at high dose levels and negative results in several Ames tests, 
a TK+/- mouse lymphoma assay, sister chromated exchange (SCE) tests in Chinese hamster ovary 
(CHO) cells and human lymphocytes, and chromosomal aberration assays with human embryonic lung 
cells, human lymphocytes and CHO cells. Negative results were also reported in two in vivo 
micronucleus and chromosomal aberration assays. However, the results of these studies have a limited 
relevance, due to the lack of bone marrow toxicity. In addition, an in vivo dominant lethal assay was 
available, from which also negative results were obtained. trans-Menthone [FL-no: 07.176] was 
genotoxic in an Ames test and in a somatic mutation and recombination test (SMART) with 
Drosophila. The observed effects were not very pronounced. Further, trans-menthone is easily 
converted to menthol, which is estimated to be overall negative in genotoxicity tests. 
Carveol and carvyl acetate [FL-no: 02.062 and 09.215] were tested in Ames test at various doses from 
10 - 560 µg/plate in the Salmonella typhimurium strains TA97, TA98, TA100, TA1535 and TA1537 
with and without S9 mix in dimethyl sulphoxide. Positive and negative controls were used. No 
mutagenicity was observed (Mortelmans et al., 1986). 
Conclusion on genotoxicity 
Only for three of the candidate substances some genotoxicity data are available, and for these three 
mainly negative results were obtained. For the supporting substances mainly negative, but also some 
positive results were obtained. The positive results were obtained in poorly reported tests, or in tests, 
which are difficult to interpret with respect to their relevance for genotoxicity.  
Overall, the genotoxic potential of this group of flavouring substances cannot be fully assessed as it is 
now. However, the data available do not indicate a genotoxic potential and therefore do not preclude 
their evaluation via the Procedure. 
For a summary of in vitro / in vivo genotoxicity data considered by EFSA, see Table 2.2 and 2.3. 
3.3. Genotoxicity Studies - Text Taken8 from EFSA FGE.211 (EFSA, 2011e) 
The following text is relevant for two substances [FL-no: 07.034 and 09.930] in this revision of 
FGE.51. These substances were evaluated based on structural similarity 1(7),8-p-menthadien-2-yl 
acetate [FL-no: 09.930]. 
The Industry has submitted data concerning genotoxicity studies for the one representative substance 
for subgroup 2.5 of FGE.19 (FGE.211), 1(7),8-p-menthadien-2-yl acetate [FL-no: 09.930] (structurally 
related to 1(7),8-p-menthadien-2-one). 
In vitro data 
The newly available data comprise a bacterial reverse mutation assay and an in vitro micronucleus 
assay with human peripheral blood lymphocytes. The genotoxicity assays have been performed on a 
commercial mixture of the representative substance 1(7),8-p-menthadien-2-yl acetate and a positional 
isomer, carvyl acetate. Carvyl acetate can be hydrolysed followed by oxidation to carvone, which has 
been evaluated by EFSA in FGE.212 (EFSA, 2009ai) and NTP (NTP, 1990b) as non-genotoxic. The 
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highest concentration of d-carvone that could be tested without cytotoxicity was 333 µg/plate 
(Mortelmans et al., 1986), i.e. the cytotoxicity was in the same range as observed for the mixture of 
1(7),8-p-menthadien-2-yl acetate/carvyl acetate. The Panel concluded that testing the commercial 
mixture of 1(7),8-p-menthadien-2-yl acetate/carvyl acetate for genotoxicity allows the evaluation of 
the genotoxic potential of 1(7),8-p-menthadien-2-yl acetate. The concentrations reported in Table 2.4 
(FGE.51Rev1) are for the mixture of substances. 
Bacterial Reverse Mutation Assay 
1(7),8-p-menthadien-2-yl acetate/carvyl acetate was tested for mutagenic activity according to OECD 
guideline 471 and in compliance with GLP (Beevers, 2010a). The test material exhibited a marked 
toxicity as indicated by thinning of the background lawn, reduced revertant counts and complete 
killing of test bacteria. However, the Panel considered the remaining number of concentrations 
without signs of toxicity sufficient to draw a conclusion on mutagenicity in this system (for details, see 
Table 2.4 of this FGE.51Rev1).  
Overall, the Panel concluded that there was no evidence of mutagenic activity of 1(7),8-p-menthadien-
2-yl acetate/carvyl acetate at concentrations up to those causing bactericidal effects. 
In vitro Micronucleus Test 
1(7),8-p-menthadien-2-yl acetate/carvyl acetate was tested for induction of micronulei in human 
peripheral blood lymphocytes according to OECD guideline 487 and in compliance with GLP 
(Whitwell, 2010b). The Panel considered that acceptable levels of cytotoxicity as judged upon the 
replication index were achieved at the top concentrations (for details see Table 2.4 of this 
FGE.51Rev1).  
Overall, the Panel concluded that no evidence of chromosomal damage or aneuploidy was observed by 
increased levels of micronucleated binucleate cells (MNBN) in the presence or absence of S9 
metabolic activation. 
A summary of the in vitro genotoxicity data is given in Table 2.4 
Discussion of Mutagenicity/Genotoxicity Data 
The commercial mixture of the representative substance 1(7),8-p-menthadien-2-yl acetate and a 
positional isomer, carvyl acetate, was tested for all three genetic endpoints: gene mutations, structural 
and numerical chromosomal aberrations. The test material did not induce gene mutations in bacteria 
and was not clastogenic and/or aneugenic in mammalian cells in vitro. Although this commercial 
mixture was cytotoxic at high concentrations, the remaining concentrations without signs of toxicity 
provide a valid data set. 
Conclusion 
The in vitro genotoxicity data on the commercial mixture of the representative substance 1(7),8-p-
menthadien-2-yl acetate [FL-no: 09.930] and a positional isomer, carvyl acetate, do not indicate 
genotoxic potential. Accordingly the four substances in FGE.211 (subgroup 2.5 of FGE.19) would be 
of no safety concern with respect to genotoxicity. 
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3.4. Genotoxicity Studies - Text Taken9 from EFSA FGE.212 (EFSA, 2009ai) and 
FGE.212Rev1 (EFSA, 2011f) 
The following text is relevant for five substances [FL-no: 07.035, 07.098, 07.126, 07.129 and 07.172] 
in this revision of FGE.51. These substances were evaluated based on structural similarity with 
isophorone [FL-no: 07.126]. 
For tetramethyl ethylcyclohexenone (mixture of isomers) [FL-no: 07.035] one in vitro and one in vivo 
study are available and have been evaluated. Seven in vitro and three in vivo studies are available for 
3,5,5 trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone). 
3,5,5 Trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone) did not induce gene mutations in 
bacteria but it induced mutations in mammalian cells in a mouse lymphoma TK assay in the absence 
of metabolic activation (it was not tested in the presence of metabolic activation) (NTP, 1986d). No 
mutations in the MLTK assay were observed in a study of O‟Donoghue et al. (O‟Donoghue et al., 
1988) at comparable concentrations. Isophorone induced chromosomal aberrations in Chinese hamster 
lung fibroblasts with and without metabolic activation (Matsuoka et al., 1996) and sister chromatid 
exchanges (SCE) in CHO cells without metabolic activation (Gulati et al., 1989). Chromosomal 
aberrations have not been observed in two other studies (Gulati et al., 1989; NTP, 1986d); however, 
the validity of the results was limited because the types of aberrations were not reported. Isophorone 
did not induce unscheduled DNA synthesis (UDS) in rat hepatocytes in vitro. In vivo, isophorone was 
tested negative in a sex-linked recessive lethal mutation assay in Drosophila (Foureman et al., 1994) 
and in two micronucleus assays in mice (McKee et al., 1987; O‟Donoghue et al., 1988). However, the 
Drosophila assay has only limited relevance and the micronucleus assays were of limited validity. 
Negative results were also observed with tetramethyl ethylcyclohexenone [FL-no: 07.035] in bacteria, 
in a sex-linked recessive lethal mutation assay in Drosophila (Wild et al., 1983) and in a mouse 
micronucleus assay (Wild et al., 1983); however, there was a mixture of isomers tested and the studies 
were only of limited validity.  
Conclusion on Genotoxicity from FGE.212 
Isophorone [FL-no: 07.126 (3,5,5-trimethylcyclohex-2-en-1-one)] is genotoxic in vitro and since there 
is some evidence of carcinogenicity in male rats and equivocal evidence of carcinogenicity in male 
mice and since a non-threshold mechanism could not be excluded based on the data currently 
available, the Panel concluded that additional data are required for isophorone in order to clarify 
whether genotoxicity occurs in vivo and whether there is a threshold for the effects observed in the 
target organs in the long-term bioassays. Therefore, an in vivo Comet assay in F344/N rats covering 
these target organs is required in addition to an in vivo bone marrow assay with oral application.  
Due to structural similarities and lack of data, the remaining substances cannot presently be evaluated 
through the Procedure [FL-no: 07.035, 07.098, 07.129 and 07.172]. Additional data on genotoxicity 
are requested for representative substances of this subgroup according to the opinion of the Panel on 
the Genotoxicity Test Strategy for Substances Belonging to Subgroups of FGE.19 (EFSA, 2008bb) 
Data submitted from Industry in reply to request for additional genotoxicity data in FGE.212 
Honma et al. (Honma et al., 1999a; Honma et al., 1999b) found that isophorone did not clearly induce 
mutations in the mouse lymphoma assay (MLA) following 3 hour treatments, but observed that it was 
mutagenic after 24 hour treatments in the absence of S9. Although only graphs are plotted, it seems 
that increases in mutation frequency (MF) that exceeded the Global Evaluation Factor (GEF) occurred 
at around 1250 ‐ 1500 μg/ml where toxicity (by relative survival) reached 70 ‐ 90 %. 
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The NTP conducted a mouse bone marrow chromosomal aberration (CA) study on isophorone. 
Groups of 8 male B6C3F1 mice (larger group sizes than required by OECD) were dosed i.p. with 
isophorone at 125, 250 and 500 mg/kg bw. The standard protocol for in vivo CA is not given on the 
NTP website. However, based on Shelby and Witt (Shelby and Witt, 1995), animals should have been 
sampled at 17 hours and, if negative, also at 36 hours. The data on the NTP website are only for bone 
marrow sampled at 36 hours. It is therefore possible that a 17 hours sample was also taken, and found 
to be negative, but the data have not been posted. Fifty cells per animal were scored for CA and no 
increases in CA were seen. No measures of toxicity were recorded, but i.p. dosing should have 
guaranteed systemic exposure. The control CA frequency was normal (2.75 %) and the positive 
control (dimethylbenzanthracene) produced a significant response in CA frequency.  
A DNA binding study was conducted in which F344‐rats and B6C3F1‐mice (the strains used in the 
NTP carcinogenicity study) were exposed to isophorone (Thier et al., 1990). Animals of both sexes 
were dosed once or five times by gavage with 500 mg/kg bw of unlabelled isophorone spiked with 
[1,3,5‐14C]‐isophorone (specific activity: 52 mCi per mmol, 1.92 GBq per mmol). An additional group 
of acute dosed male rats received undiluted 
14
C‐isophorone for increased sensitivity. Rats and mice 
were maintained for 24 hours in closed metabolic cages. Twenty four hours after exposure, livers and 
kidneys (the tumour target tissues) were removed from the animals. DNA was isolated through 
hydroxyapatite chromatography and radioactivity was measured by liquid scintillation counting. No 
positive controls were included. Also no untreated controls were included, but, except for the liver 
sample of one mouse in the five times dose group, radioactivity values were within 2σ of background 
(6 dpm). Radioactivity values therefore did not indicate significant attachment of radioactivity to 
DNA. From these results it can be concluded that neither isophorone nor its metabolites bind 
covalently to DNA. 
In addition, a report by Morishita et al. (Morishita et al., 1997b) submitted to EPA (EPA, 1997), is 
relevant and appears to have been previously submitted only as an abstract. This study was designed to 
investigate whether isophorone and/or α2μ‐globulin10 might be involved in the induction of preputial 
gland tumours in F‐344 rats (10/sex/dose group). A series of experiments was performed in order to 
study several parameters including: 
 binding of isophorone to DNA of kidney and preputial gland. Groups of 10 male rats were dosed 
by gavage with 500 mg/kg of [
14
C]‐isophorone (specific activity 14.65 mCi/mmol; 100 
μCi/animal). Positive control animals were dosed with 3H‐labeled methyl nitrosourea. 
 DNA adduct detection by 32P‐postlabeling in young adult male and female rats (7 per group) dosed 
by gavage with 0, 250 or 500 mg/kg isophorone for five days. 
Extraction of preputial gland and kidney DNA from rats treated with single 500 mg/kg labeled doses 
yielded no evidence of isophorone binding to DNA, whereas the positive control showed significant 
binding to DNA of preputial gland and kidney. These negative results with isophorone were confirmed 
in the 
32
P ‐postlabeling assays.  
Discussion of the additional data 
Conflicting results were reported in two valid studies with the mouse lymphoma assay (MLA): one 
negative (O‟Donoghue et al., 1988) and one positive (NTP, 1986d) at comparable concentrations. 
Mixed results were also reported in two studies of limited validity: one negative (Honma et al., 1999a) 
and one positive (Honma et al., 1999b). Another negative result was reported in a study (McKee et al., 
1987), the validity of which cannot be evaluated. In the light of the clearly negative results in two 
valid bacterial gene mutation tests (Ames test) and in a valid Sex Linked Recessive Lethal Mutations 
test (SLRL) in Drosophila, and taking into account the lack of specificity and high sensitivity of the 
MLA, overall the results presently available are considered of questionable relevance. The Panel 
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agrees that isophorone demonstrates some genotoxic activity in vitro but that the new data demonstrate 
lack of clastogenicity in vivo. In addition, the new DNA-binding data from two separate studies 
provide convincing evidence that isophorone does not induce tumours via a genotoxic mechanism. On 
the basis of these data it may be argued that there is no need to perform further in vivo genotoxicity 
studies such as the Comet assay or bone marrow micronucleus test. Thus, based on the data available 
the Panel concluded in FGE.212Rev1 that there is no concern with respect to genotoxicity of 
isophorone. 
A summary of the in vitro and in vivo genotoxicity data from FGE.212Rev1 is given in Tables 2.5 and 
2.6. 
3.5. EFSA Considerations  
Data not available for the JECFA at the time of evaluation (59
th
 meeting) for cyclohexanone [FL-no: 
07.148] have been considered by EFSA. Results from in vitro genotoxicity studies with 
cyclohexanone, carried out by NTP, have been published on the NTP website (NTP, 2007). From the 
technical information also provided there, it can be concluded that the tests by NTP are reliable. A set 
of Ames tests with Salmonella strains TA98, TA100, TA1535 and TA1537) and a study with mouse 
lymphoma cells (L5178Y; tk
+
/-), including cloning efficiency and colony sizing provided convincingly 
negative results. The tests were carried out with and without metabolic activation at cyclohexanone 
levels up to 10000 microg/plate in the Ames tests and up to 5000 microg/ml in the mouse lymphoma 
assay. For a summary of these studies see Table 2.7. 
The Panel noted that cyclohexanone has also been studied in long term carcinogenicity studies in mice 
(up to 6.2 g/kg bw/day) and rats (up to 0.65 g/kg bw/day) (Lijinsky and Kovatch, 1986). The 
substance was tested up to the maximum tolerated dose levels and the overall conclusion from these 
studies was that cyclohexanone is not carcinogenic. In an evaluation of these studies the IARC 
concluded that the substance was not classifiable as to its carcinogenicity to humans (IARC, 1989). 
For seven candidate substances [FL-no: 07.034, 07.035, 07.098, 07.126, 07.129, 07.172 and 09.930] it 
has been concluded in FGE.211 and FGE.212Rev1, that a concern for genotoxicity, indicated by the 
presence of a structural alert, could be ruled out based on experimental data for representative 
substances.  
Based on these results the Panel concluded that the data available do not preclude evaluation of the 20 
JECFA evaluated alicyclic ketones, secondary alcohols and related esters through the Procedure. 
4. Application of the Procedure 
4.1. Application of the Procedure to 20 Alicyclic Ketones, Secondary Alcohols or Related 
Esters Evaluated by the JECFA (JECFA, 2003a): 
According to the JECFA six of the substances belong to structural class I and 14 to structural class II 
using the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded all 20 alicyclic ketones, secondary alcohols or related esters at step A3 in the 
JECFA Procedure – i.e. the substances are expected to be metabolised to innocuous products (step 2) 
and the intakes for all substances are below the thresholds for structural classes I and II (step A3).  
In conclusion, the JECFA evaluated all 20 substances as to be of no safety concern at the estimated 
levels of intake as flavouring substances based on the MSDI approach. 
The evaluations of the 20 substances are summarised in Table 3.1: Summary of Safety Evaluation of  
Alicyclic Ketones, Secondary Alcohols or Related Esters (JECFA, 2003a). 
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4.2. Application of the Procedure to 17 Secondary Alicyclic Saturated and Unsaturated 
Alcohols, Ketones and Esters Containing Secondary Alicyclic Alcohols by EFSA in 
FGE.09Rev3 (EFSA, 2011x): 
Seventeen flavouring substances were evaluated in FGE.09Rev3. Thirteen substances are classified 
into structural class I, three into structural class II and one into structural class III using the decision 
tree approach presented by Cramer et al. (Cramer et al., 1978). 
Sixteen substances were concluded at step A3 using the EFSA Procedure – i.e. the substances are 
expected to be metabolised to innocuous products (step 2) and the estimated daily intakes for 15 
substances are below the thresholds of concern for their structural classes (step A3). 
For one substance methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520] the estimated daily 
intake exceeds the threshold of concern for structural class II and since the substance is not 
endogenous the substance proceeds to step A5. 
A 90 day study in rats has been performed for [FL-no: 09.520] from which a No Observed Adverse 
Effect Level (NOAEL) of 100 mg/kg body weight (bw)/day could be derived. This NOAEL provides a 
margin of safety of nearly 10
4
 compared to the daily intake of 0.013 mg/kg bw/day for methyl 3-oxo-
2-pentyl-1-cyclopentylacetate. Therefore, [FL-no: 09.520] does not pose a safety concern when used 
at estimated levels of intake, based on the MSDI approach, as a flavouring substance 
One flavouring substance [FL-no: 07.207] was not expected to be metabolised to innocuous products 
and was therefore evaluated via the B-side in the EFSA Procedure. The estimated intake is below the 
threshold, but no adequate No Observed Adverse Effect Level (NOAEL) could be provided for the 
substance or a structurally related substance – therefore additional data are required for this substance. 
In conclusion, the Panel considered that 16 of the substances evaluated through the Procedure were of 
no safety concern at the estimated levels of intakes based on the MSDI approach. For one substance 
additional data were required. 
The stepwise evaluations of the 17 substances are summarised in Table 3.2: Summary of Safety 
Evaluation Applying the Procedure (EFSA, 2011x). 
4.3. EFSA Considerations 
The Panel agrees with the application of the Procedure as performed by the JECFA for the 20 
substances in the group of alicyclic ketones, secondary alcohols and related esters. 
 
5. Conclusions 
The JECFA has evaluated a group of 25 flavouring substances consisting of alicyclic ketones, 
secondary alcohols and related esters at its 59
th
 meeting. Two of the JECFA-evaluated substances are 
not in the Register (4-methyl cyclohexanone (JECFA no: 1104) and (E)-2-(2-octenyl) cyclopentanone 
(JECFA no: 1116)). Ten of the remaining 23 JECFA-evaluated substances are alpha,beta-unsaturated 
ketones or precursors for such, which structural property has been recognised as a structural alert for 
genotoxicity. Seven of these 10 candidate substances [FL-no: 07.034, 07.035, 07.098, 07.126, 07.129, 
07.172 and 09.930] have been considered with respect to genotoxicity in FGE.211 (EFSA, 2011e) or 
FGE.212Rev1 (EFSA, 2011f), and the Panel concluded that the data available ruled out the concern 
for genotoxicity and accordingly these seven substances can be evaluated through the Procedure. For 
the remaining three substances [FL-no: 07.033, 07.094 and 07.112] considered with respect to 
genotoxicity in FGE.212Rev1 a final conclusion of genotoxic properties could not be reached and 
additional data were requested. These three substances will therefore not be considered in this revision 
of FGE. 51. This consideration therefore deals with 20 JECFA-evaluated substances. 
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The Panel concluded that the 20 substances in the JECFA group of alicyclic ketones, secondary 
alcohols and related esters are structurally related to the group of 17 secondary alicyclic saturated and 
unsaturated alcohols, ketones and esters containing secondary alicyclic alcohols evaluated in the 
Flavouring Group Evaluation 09, Revision 3 (FGE.09Rev3). 
The Panel agrees with the application of the Procedure as performed by the JECFA for the 20 
substances considered in this FGE. 
For all substances evaluated through the Procedure use levels are needed to calculate the mTAMDIs in 
order to identify those flavouring substances that need more refined exposure assessment and to 
finalise the evaluation. 
In order to determine whether the conclusion for the JECFA-evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity tests are available for all 20 substances.  
For all 20 JECFA-evaluated alicyclic ketones, secondary alcohols and related esters [FL-no: 02.209 
07.034, 07.035, 07.045, 07.095, 07.098, 07.126, 07.129, 07.148, 07.149, 07.172, 07.179, 07.180, 
07.257, 09.027, 09.140, 09.160, 09.230, 09.464 and 09.930] the Panel agrees with the JECFA 
conclusion, “No safety concern at estimated levels of intake as flavouring substance” based on the 
MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY  
Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Alicyclic Ketones, Secondary Alcohols and Related Esters (JECFA, 2002d) 
FL-no 
JECFA-no 







Solubility in ethanol 
2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 













































































cyclohexen-1-one.  Mixture 
of diastereoisomers in 













































25 % of each  (EFFA, 
2012b).  
Min assay 94 % secondary 
comp. 2-isobutyl 
cyclohexanone 2-2.5 % 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Alicyclic Ketones, Secondary Alcohols and Related Esters (JECFA, 2002d) 
FL-no 
JECFA-no 







Solubility in ethanol 
2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Alicyclic Ketones, Secondary Alcohols and Related Esters (JECFA, 2002d) 
FL-no 
JECFA-no 







Solubility in ethanol 
2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
































































Racemic mixture of (E)- 
and (Z)-isomers (EFFA, 
2010a).  
The double bond occurs 
mainly as E-isomer (at least 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Alicyclic Ketones, Secondary Alcohols and Related Esters (JECFA, 2002d) 
FL-no 
JECFA-no 







Solubility in ethanol 
2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 














































































77-79 (0.1 hPa) 
 






diastereoisomers (25 % of 
each)  (EFFA, 2012b). 
Registername to be 




1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 % ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
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TABLE 2: GENOTOXICITY DATA  




EU Register name 
JECFA name 








DNA damage B. subtilis H17(rec+), 
M45 (rec–) 





DNA damage B. subtilis H17(rec+), 
M45 (rec-) 





Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537, TA1538 
5 concentrations, up to 
cytotoxicity or  max 
36000 g/plate. 





Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 





Foreward mutation test Mouse lymphoma 
L5178Y Tk+/- cells 
0 – 1600 g/ml Positive





Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
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EU Register name 
JECFA name 
Structural formula End-point Test system Maximum 
concentration 
Results Reference 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
2.9 - 2900 µgd/plate Negativea (Florin et al., 1980) 
Chromosomal  Chinese hamster ovary  
cells aberration 
7.5 µl/ml Negativea (Aaron et al., 1985) 
Chromosomal  Human lymphocytes 
aberration 
9.8 - 980 µgd/ml Positivea (Lederer et al., 1971) 
Chromosomal  Human lymphocytes 
aberration 
0.005 - 0.1 µgd/ml Positivea (Dyshlovoi et al., 1981) 
Sister chromatid exchange Chinese hamster ovary  
cells 
7.5 µl/ml Negativeb 
Positivec 





Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 






Sex-linked recessive lethal 
mutation 
D. melanogaster 10 mM Negative Wild et al., 1983 
Micronucleus assay NMRI mice (4/group) 0, 166, 333, 500 mg/kg 
bw; single dose, 30 hrs 
expression time 





Sex-linked recessive lethal 
mutation 
D. melanogaster 0.1 ml/100 ml Negative (Goncharova, 1970) 
a With and without metabolic activation. 
b Without metabolic activation. 
c With metabolic activation. 
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Table 2.2: GENOTOXICITY (in vitro) EFSA / FGE.09Rev3 (EFSA, 2011x) (substances in brackets are JECFA-evaluated substances) 
Chemical Name [FL-
no] 
Test system Test Object  Concentration  Result  Reference  Comments 
(Menthol [02.015]) Ames test  S. typhimurium TA92, TA94, TA98, TA100, 
TA1535, TA1537 
0, and 6 concentrations up 
to 5000 µg/plate  
Negative1  (Ishidate et al., 1984) d,l-Menthol was used. The study is considered valid.   
Ames test (preincubation method) S. typhimurium TA97, TA98, TA100, TA1535 3 - 666 µg/plate  Negative1 (Zeiger et al., 1988) d,l-Menthol was used. The study is considered valid.  
Ames test  S. typhimurium TA98, TA100, TA2637 0, 5 - 500 µg/plate  Negative1  (Nohmi et al., 1985) d,l-Menthol was tested. The highest concentrations 
were cytotoxic. The study is considered valid. 
Ames test  S. typhimurium TA98, TA100, TA2637 0, 20 - 500 µg/plate  Negative1  (Nohmi et al., 1985) l-Menthol was tested. The highest concentrations 
were cytotoxic. The study is considered valid. 
Ames test  S. typhimurium TA98, TA100, TA1535, TA1537 0, 6.4, 32, 160, and 800 
µg/plate  
Negative1  (Andersen and Jensen, 
1984b) 
No indication of which enantiomer was used. In the 
absence of metabolic activation, the highest 
concentration was cytotoxic. The study is considered 
valid. 
Ames test  E. coli WP2 uvrA (Trp-) 100 - 800 µg/plate  Negative  (Yoo, 1986) l-Menthol was used. The article is not in English. The 
validity of the study cannot be evaluated. It is unclear 
whether metabolic activation or a control group was 
used. 
Ames test  S. typhimurium TA97A, TA98, TA100, TA102 0, 5 - 800 µg/plate  Negative1  (Gomes-Carneiro et al., 
1998) 
(-)-Menthol was used. The range of concentrations 
tested varied between the different strains. 
Cytotoxicity was observed with the highest 
concentrations tested with TA97A and, in the 
presence of metabolic activation, the highest 
concentration tested with TA102. The study is 
considered valid. 
Rec assay  B. subtilis H17, M45 Up to 10000 µg/disk  Positive (Yoo, 1986) l-Menthol was used. Inhibition zone for rec- and rec+ 
was 42 and 23 mm, respectively. The article is not in 
English. It is not clear from the study whether 
metabolic activation, or a control group was used. 
The validity of this study cannot be assessed. The 
method (rec-assay) has poor predictive value. 
Rec assay  B. subtilis H17, M45 20 µg/disk  Negative (Oda et al., 1979) l-Menthol was used. The article is not in English. 
Only one concentration level is mentioned at a table. 
No data on metabolic activation or control group. The 
validity of this study cannot be evaluated. The 
method (rec-assay) has poor predictive value. 
Alkaline elution assay Rat hepatocytes  0, 0.1 - 1.3 mM  (203.2 
µg/ml4) 
Negative (Storer et al., 1996) The experiment employed d-Menthol. An increase in 
DNA breaks was only observed at concentrations 
associated with cytotoxicity. The authors concluded 
that this was a false-positive result. The study is 
considered valid.                          
Sister chromatid exchange Chinese hamster ovary cells 5 - 50 amd 0, 2 - 25 µg/ml3 
0, 16 - 167 µg/ml 2 
Negative1  (Ivett et al., 1989) d,l-Mentol was used. The compound was tested up to 
toxic or nearly toxic concentration levels. The study 
is considered valid. 
Sister chromatid exchange Human lymphocytes 0, 0.1, 1, 10 mM  (1563 
µg/ml4) 
Negative1  (Murthy et al., 1991) The study is considered valid. 
Cytogenetic assay Human embryonic lung cells 0, 0.1, 1, 10 µg/ml  Negative  (Food and Drug 
Research Laboratories, 
Inc., 1975a) 
The report does not  mention exogenous metabolic 
activation. The study is considered valid. 
Chromosome aberration Chinese hamster fibroblasts 0 and three concentrations 
up to 200 µg/ml  
Negative3  (Ishidate et al., 1984) The maximum concentration (cytotoxic) was selected 
by a preliminary test. The study is considered valid. 
Chromosome aberration Chinese hamster ovary cells 0, 50 - 250 µg/ml  Negative1  (Ivett et al., 1989) d,l-Mentol was used. The compound was tested up to 
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Table 2.2: GENOTOXICITY (in vitro) EFSA / FGE.09Rev3 (EFSA, 2011x) (substances in brackets are JECFA-evaluated substances) 
Chemical Name [FL-
no] 
Test system Test Object  Concentration  Result  Reference  Comments 
toxic or nearly toxic concentration levels. The study 
is considered valid. 
Chromosome aberration Human lymphocytes 0, 0.1, 1, 10 mM (1563 
µg/ml4)  
Negative1  (Murthy et al., 1991) The study is considered valid. 
Gene mutation assay Mouse lymphoma L5178Y TK+/-cells 0, 12.5 - 200 µg/ml  Negative1  (Myhr and Caspary, 
1991) 
d,l-Menthol was used. The maximum concentration 




Ames test  S. typhimurium TA97, TA98, TA100, TA1535, 
TA1537 
0, 6.4 - 800 µg/plate  Positive1  (Andersen and Jensen, 
1984b) 
Concentrations were selected based on preliminary 
experiments. In absence of metabolic activation, 
menthone was mutagenic only to strain TA1537 at 
6.4 and 32 g/ml (slightly less than 2-fold increase in 
mutation frequency), but not at higher (toxic) 
concentrations. Also in absence of metabolic 
activation, there was a concentration dependent 
increase in number of TA97 strain revertants (up to 
4-fold increase at 600 g/l). It was stated that 
metabolic activation did not enhance the 
mutagenicity of menthone. The study is considered 
valid. 
Cyclopentanol [02.135]  Modified Ames test S. typhimurium G46, TA98, TA100, TA1535, C3076, 
TA1537, D3052, TA1538  
E. coli WP2, WP2 uvrA- 
0, 0.1 - 1000 µg/ml  Negative1  (McMahon et al., 1979) The study was performed with agar plates containing 
the following concentration gradients: 0.1 - 1, 1 - 10, 
10 - 100, and 100 - 1000 g/ml. The study is 
considered valid, although tabulated data on 
cyclopentanol were not presented. 
(Cyclohexanone 
[07.148]) 
Ames test  S. typhimurium TA98, TA100, TA1535, TA1537 0, 33 - 10000 µg/plate  Negative1  (Haworth et al., 1983) The highest level tested was the highest of either 
10000 g/plate, limit of solubility or maximal non-
toxic concentration. The test was run twice. Both rat 
and hamster liver S9 were used. The test is 
considered valid. 
Ames test  S. typhimurium TA98, TA100, TA1535, TA1537 0, 3 µmol/plate  Negative1  (Florin et al., 1980) A preliminary assay was performed with the four 
strains using only one concentration level (3 
mol/plate). This assay gave uncertain results. In 
addition, strains TA98 and TA100 were exposed to 
0.03 - 30 mol/plate. The validity of the study cannot 
be evaluated. 
Ames test  S. typhimurium TA98, TA100, TA1535, TA1537 NR Positive (Massoud et al., 1980) Only an abstract is available. No reporting with 
respect to metabolic activation. The substance was 
also tested with Bacillus subtilis. With this specie, 
toxicity was found as well as a positive response. The 
validity of the study cannot be evaluated because of 
lack of experimental information. 
Cytogenetic assay Human leukocytes 0.1 - 10 mM  Inconclusive3  (Collin, 1971) The study report contains little experimental detail. 
Gaps, but no increase in breaks, were observed 
without any dose response relationship. There was no 
information with respect to cytotoxicity or presence 
of a control group. Only a statement on observations 
from 12 cells per concentration was given, but the 
total number of cells studied was not specified. The 
study is inadequate. 
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Table 2.2: GENOTOXICITY (in vitro) EFSA / FGE.09Rev3 (EFSA, 2011x) (substances in brackets are JECFA-evaluated substances) 
Chemical Name [FL-
no] 
Test system Test Object  Concentration  Result  Reference  Comments 
Chromosomal aberration Human lymphocytes 0, 0.005 -  0.1 µg/ml Positive  (Dyshlovoi et al., 1981) Article is not in English. Only an abstract available in 
English. The validity of the study cannot be 
evaluated.             
Gene mutation (HPRT) Chinese hamster ovary cells 0, 7.5 µg/ml  Negative1  (Aaron et al., 1985) Only an abstract is available with limited 
experimental information. The validity of the study 
cannot be evaluated.  
Chromosomal aberration Chinese hamster ovary cells 0, 7.5 µg/ml  Negative1  (Aaron et al., 1985) Only an abstract is available with limited 
experimental information. The validity of the study 
cannot be evaluated.  
Sister chromatic exchange Chinese hamster ovary cells 0, 7.5 µg/ml  Positive3  
Negative2 
(Aaron et al., 1985) Only an abstract is available with limited 
experimental information. The validity of the study 
cannot be evaluated. 
Cyclohexanol [02.070] Ames test  S. typhimurium TA98, TA1535, TA1537, TA1538 500 - 10000 µg/plate3 
500 - 15000 µg/plate2 
Negative1  (Barsky, 1976) The highest concentrations showed cytotoxicity. The 
study is considered valid. 
Ames test  S. typhimurium TA98, TA100, TA1535, TA1537 0, 10 - 3333 µg/plate Negative1  (Haworth et al., 1983) The highest level tested was the highest of either 
10000 g/plate, limit of solubility or maximal non-
toxic concentration. Both rat and hamster liver S9 
were used. The test was run twice. The study is 
considered valid. 
Chromosomal aberration Human leukocytes  0.1 - 10 mM  Inconclusive3 (Collin, 1971) The study report contains little experimental detail. 
Gaps, but no increase in breaks, were observed 
without any dose response relationship. There was no 
information with respect to cytotoxicity or presence 
of a control group. Only a statement on observations 
from 12 cells per concentration was given, but the 
total number of cells studied was not specified. The 
study is inadequate. 
(Cyclohexyl acetate 
[09.027]) 
DNA damage B. subtilis H17(rec+), M45 (rec–) 19 mg/disc Negative1 (Yoo, 1986)  
(Cyclohexyl butyrate 
[09.230]) 
DNA damage B. subtilis H17(rec+), M45 (rec-) 19 mg/plate Negative1 (Oda et al., 1979)  
(Cycopentanone 
[07.149]) 
Reverse mutation S. typhimurium TA98, TA100, TA1535, TA1537 2.5 - 2500 mg/plate Negative1 (Florin et al., 1980)  
(2,2,6-Trimethyl cyclo-
hexanone [07.045]) 




Reverse mutation S. typhimurium TA98, TA100, TA102, 
TA1535,TA1537 
5 mg/plate Negative1 (Thompson, 2000) Valid study in compliance with the OECD Guideline 
-471. 
Reverse mutation E. coli WP2 uvrA 5 mg/plate Negative1 (Wagner and Klug, 
2000) 
Valid study in compliance with the OECD Guideline 
-471. 




(Ross and Harris, 
1979b) 
Pre-GLP study - not possible to assess the reliability 
of these studies. 
Forward mutation Test Mouse lymphoma cells L5178y 100 - 325 µg/L Negative1 (Cifone, 2001) Valid study and in compliance with OECD Guideline 
476. 
(Carveol [02.062]) Ames test (pre-incubation) S. typhimurium TA98, TA100, TA1535, TA1537 560 µg/plate Negative (Mortelmans et al., 
1986) 
 





Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537 and TA1538 
78, 156, 312, 625, 1250, 
2500 or 10 000 μg/plate 
Negativea,b (Morimoto, 2005) The JECFA evaluated the racemate of L-menthyl 
(R,S)-3-hydroxybutyrate. 
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Table 2.2: GENOTOXICITY (in vitro) EFSA / FGE.09Rev3 (EFSA, 2011x) (substances in brackets are JECFA-evaluated substances) 
Chemical Name [FL-
no] 
Test system Test Object  Concentration  Result  Reference  Comments 
Reverse mutation E. coli WP2uvrA 78, 156, 312, 625, 1250, 
2500 or 10 000 μg/plate 
Negativea,b (Morimoto, 2005)  
NA: Not applicable. 
NR: Not reported. 
1 With and without S9 metabolic activation. 
2 With S9 activation. 
3 Without S9 activation. 
4 Calculated based on molecular weight of menthol = 156.3 g/mol. 
5 Marked differential toxicity was seen at dose levels above 25 µmol/plate. No observations were noted at lower dose levels. 
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Table 2.3: GENOTOXICITY (in vivo) EFSA / FGE.09Rev3 (EFSA, 2011x) (substances in brackets are JECFA-evaluated substances) 
Chemical Name  Test System Test Object  Route Dose Result  Reference  Comments 
(Menthol [02.015]) Host mediated 
mutation assay 
S. typhimurium  
TA1530 and G46;  
S. cerevisiae D3 
inoculated in mice (7-
9 animals/group) 
Gavage  0, 1.45 - 5000 mg/kg bw 
(single dose) 
0, 1150 mg/kg bw/day 
(repeated doses) 
Equivocal (Food and Drug Research 
Laboratories, Inc., 1975a) 
Negative results, with exception of 
the combination S. typhimurium  
TA1530 - 5000 mg/kg bw and S. 
cerevisiae D3 - 1150 mg/kg bw/day. 
This study is considered valid, but 
the equivocal result might have  low 
relevance since the  effect was only 
observed at very high (lethal) dose 
levels. 
In vivo cytogenetic assay Male rat bone marrow 
cells 
Gavage 0, 1.45 - 3000 mg/kg bw 
(single dose) 
0, 1150 mg/kg bw/day 
(repeated doses) 
Negative (Food and Drug Research 
Laboratories, Inc., 1975a)                             
Oral DL50 was determined as 940 
mg/kg bw. The study is considered 
valid but the negative result is of 
limited relevance, since no effect on 
mitotic index was observed. 
However, testing at higher dose 
levels may not have been possible, 
due to lethality. 
In vivo micronucleus 
assay 
B6C3F1 male mouse 
bone marrow cells 
Intra peritonal 0, 250 - 1000 mg/kg bw/day, 
during 3 days 
Negative (Shelby et al., 1993) d,l-Menthol was used. The study is 
considered valid, but the negative 
result is of limited relevance, since 
no toxicity to the bone marrow was 
observed. However, testing at higher 
dose levels was not possible, because 
the highest dose caused 50 % 
lethality. 
In vivo dominant lethal 
assay 
Male rat fertility, 
spermatozoa 
Gavage 0, 1.45 - 3000 mg/kg bw 
(single dose) 
0, 1150 mg/kg bw/day 
(repeated doses) 
Negative (Food and Drug Research 
Laboratories, Inc., 1975a) 
This study is considered valid. 
(trans-Menthone [07.176]) In vivo SMART assay D. melanogaster – flr3 
x mwh cross  
Whole body 0, 1.3 µl/disk Positive (Franzios et al., 1997) Somatic Mutation and 
Recombination Test. Only one dose 
level (1.29 l/disk; slightlyhigher 
than the LD50) was tested. A two-fold 
increase in mutation frequency as 
compared to control was observed. 
Menthone was not recombinogenic. 
The validity of this study is unclear. 
(Cyclohexanone [07.148]) In vivo sex-linked 
recessive lethal mutation 
D. melanogaster  NR 
3 days exposure 
0, 1 l/ml Negative (Goncharova, 1970) Article in Russian. Only an abstract 
available in English. The validity of 
this study cannot be assessed. 
Cyclohexanol [02.070] In vivo sex-linked 
recessive lethal mutation 
D. melanogaster NR 
3 days exposure 
0, 1 l/ml Negative (Goncharova, 1970) The validity of the study cannot be 
evaluated. 
In vivo micronucleus test NMRI mouse bone 
marrow  
Oral  500 - 1500 mg/kg bw Negative (Gelbke, 1991) The study is considered valid. The 
negative result of this study is of 
limited relevance, since no bone 
marrow toxicity could be detected. 
Testing at higher dose levels might 
not have been possible due to 
observed general toxicity at the 
highest dose. 
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Table 2.3: GENOTOXICITY (in vivo) EFSA / FGE.09Rev3 (EFSA, 2011x) (substances in brackets are JECFA-evaluated substances) 
Chemical Name  Test System Test Object  Route Dose Result  Reference  Comments 
Methyl 3-oxo-2-pentyl-1-
cyclopentylacetate [09.520] 
Micronucleus test ICR mice Intra peritonal 280, 560 & 1120 mg/kg bw Negative (Gudi and Krsmanovic, 1998) Valid study in compliance with the 
OECD Guideline 474. 
Unscheduled DNA 
Synthesis 
Rat hepatocytes Intra peritonal 333.3 & 1000 mg/kg bw Negative (Durward, 2001) Valid study in compliance with the 
OECD Guideline 486.  
NR: Not reported 
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Table 2.4: GENOTOXICITY (in vitro) from FGE.211 
FL-no 
JECFA-no 





Reverse Mutation S. typhimurium TA98, TA100, 
TA1535, TA1537 and TA102 
1.6*, 8*, 40*, 200, 1000 and 5000 μg/plate [1,2] Negative (Beevers, 2010a) * Concentration 
without cytotoxicity. 
S. typhimurium TA98, TA1535 
and TA1537 
15.6*, 31.3*, 62.5*, 125, 250 and 500 μg/plate [2,3] Negative 
S. typhimurium TA100 and 
TA102 
78.1*, 156.3*, 312.5, 625, 1250 and 2500 μg/plate [2,3] Negative 
S. typhimurium TA98 and TA100 156.3*, 312.5, 625, 1250, 2500 and 5000 μg/plate [4,5] Negative 
S. typhimurium TA1535, TA1537 
and TA102 
78.1*, 156.3*, 312.5, 625, 1250 and 2500 μg/plate [4,5] Negative 
S. typhimurium TA100 25*, 50*, 100*, 200 and 400 μg/plate [2,3] Negative 
S. typhimurium TA98 50*, 100*, 200*, 400 and 800 μg/plate [4,5] Negative 
S. typhimurium TA100, TA1535, 
TA1537 and TA102 
25*, 50*, 100*, 200 and 400 μg/plate [4,5] Negative 
Micronucleus induction Human peripheral blood 
lymphocytes 
80, 90 and 110 μg/ml [3,6]; 
200, 300 and 400 μg/ml [5,6] 
Negative (Whitwell, 2010b) 50 to 65 % 
cytotoxicity at top 
concentrations. 20, 50, 80 and 100 μg/ml 
[3,7] 
Negative 
[1] With and without S9 metabolic activation. 
[2] Plate incorporation method. 
[3] Without S9 metabolic activation. 
[4] Pre-incubation method. 
[5] With S9 metabolic activation. 
[6] 3-hour incubation with 21-hour recovery period. 
[7] 24-hour incubation with no recovery period. 
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Table 2.5: GENOTOXICITY (in vitro) from FGE.212Rev1 
Chemical Name [FL-no]  Test System Test Object  Concentration Reported 
Result  
Reference  Comments e 
Tetramethyl ethylcyclohexenone 
(mixture of isomers [07.035] 
Reverse mutation S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
5 concentrations up to 
cytotoxicity,  or max. 3600 
µg/plate 
Negativea (Wild et al., 1983) Limited validity (no TA 102 or E. Coli); 




Reverse mutation S. typhimurium TA97, TA98, TA100, 
TA1535, TA1537 
33 - 10 000 μg/plate Negativea (Mortelmans et al., 1986) Valid. 
Mutation S. typhimurium TA98, TA100, TA1535, 
TA1537 
33 - 10 000 μg/plate Negativea (NTP, 1986d) NTP study carried out according to standard US-
EPA guideline; result is considered as valid. 
Mutation L5178YTk+/– mouse lymphoma cells 67 - 810 μg/ml Negativeb (McKee et al., 1987) Validity cannot be evaluated (tested with S9; 
abstract only with very limitred information). 
Mutation L5178YTk+/– mouse lymphoma cells 130 - 1300 μg/ml Negativec (McKee et al., 1987) Validity cannot be evaluted (tested without S9; 
abstract only with very limitred information). 
Mutation L5178YTk+/– mouse lymphoma cells 0.089 - 0.89 μg/ml Negativec (O‟Donoghue et al., 1988) Valid according to current guidelines. 
Mutation L5178YTk+/– mouse lymphoma cells 0.13 - 1.3 μg/ml Negativeb  (O‟Donoghue et al., 1988) Valid according to current guidelines. 
Mutation L5178YTk+/– mouse lymphoma cells  1200 μg/ml Positiveb 
 
(NTP, 1986d) NTP study carried out according to standard US-
EPA guideline; Not tested with S9. Result is 
considered as valid. 
Mutation L5178YTk+/– mouse lymphoma cells Not reported (however, up to 
cytotoxic concentrations) for 3 
hours exposure.  
Negativea (Honma et al., 1999a) Limited validity since data were presented in a 
summarized table format only (as a result of an 
international collaborative study). 
Mutation L5178YTk+/– mouse lymphoma cells Up to 1500 μg /ml Positiveb 
 
(Honma et al., 1999b) Limited validity since mutation frequencies were 
not reported in table format. Tested only in the 
absence of S9. Isophorone was mutagenic after 
24 hours treatments in the absence of S9. 
Although only graphs are plotted, it seems that 
increases in MF that exceeded the Global 
Evaluation Factor occurred at around 1250-1500 
μg/ml where toxicity (by relative survival) 
reached 70-90 %. 
Chromosomal aberration Chinese hamster ovary cells 5 - 1600 μg/ml Negativea (Gulati et al., 1989) 
 
Limited validity (not clear if gaps were included 
in the scores). 
Chromosomal aberration Chinese hamster ovary cells 250 - 1600 μg/ml Negativea (NTP, 1986d) 
 
NTP study carried out according to standard US-
EPA guideline; result is considered as valid. 
Chromosomal aberration  Chinese hamster lung fibroblasts  0 - 1250b g/ml  
0 - 1500c g/ml 
Positivea (Matsuoka et al., 1996) 
 
Valid. Exposed to isophorone for 6 hrs with a 
recovery period of 18 hours. 
Chromosomal aberration  Chinese hamster lung fibroblasts  250 - 1000 mg/ml Negativea (Matsuoka et al., 1996) 
 
Valid. Exposed to isophorone without metabolic 
activation for 24 hours or 48 hours, cytotoxic at 
highest concentrations. 
Sister chromatid exchange Chinese hamster ovary cells 5 - 1600 mg/ml Positiveb,d  (Gulati et al., 1989) Valid (pos – S9; neg + S9). 
Sister chromatid exchange Chinese hamster ovary cells 160 - 1000 mg/ml Negativea (NTP, 1986d) NTP study carried out according to  
Standard US-EPA guideline; result is 
considered as valid. 
Unscheduled DNA synthesis Rat hepatocytes 0.005 - 0.4 µl/ml Negative (O‟Donoghue et al., 1988) Valid according to current guidelines. 
Unscheduled DNA synthesis Rat hepatocytes 5 - 200 l/ml Negative
a (McKee et al., 1987) Validity cannot be evaluated (abstract only with 
very limited information). 
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Table 2.5: GENOTOXICITY (in vitro) from FGE.212Rev1 
Chemical Name [FL-no]  Test System Test Object  Concentration Reported 
Result  
Reference  Comments e 
Carvone (isomer not specified) Gene mutation S. typhimurium TA1535, TA1537, TA98, 
TA100 
3 µmol/plate Negative (Florin et al., 1980) Insufficient validity (spot test, not according to 
OECD guideline, methods and results 
insufficiently reported). Isomer (D or L) not 
reported. 
Rec assay Bacillus subtilis H17 (rec+) and M45 (rec-
) 
0.6 ml/disc Negative (Matsui et al., 1989) The test system used is considered inappropriate. 
d-Carvone [07.146] Gene mutation  S. typhimurium TA1535, TA98, TA100, 
TA1537 
333 µg/plate Negativea (NTP, 1990b) Valid. 
Gene mutation 
(preincubation) 
S. typhimurium TA1535, TA98, TA100, 
TA1537 
560 µg/plate Negative (Mortelmans et al., 1986) Valid. 
Sister chromatid exchange Chinese hamster ovary cells 502 µg/ml Positivea (NTP, 1990b) Valid. 
Chromosomal aberration Chinese hamster ovary cells 400 µg/ml Positivea (NTP, 1990b) Valid. 
a: With and without metabolic activation. 
b: Without metabolic activation. 
c:  With metabolic activation.  
d: Cytotoxic at next highest dose tested (1600 mg/ml). 
e: Validity of genotoxicity studies: 
 Valid. 
 Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate  test system). 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
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Table 2.6: GENOTOXICITY (in vivo) from FGE.212Rev1 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments a 
Tetramethyl ethylcyclohexenone 
(mixture of isomers [07.035] 
Sex-linked recessive 
lethal mutation 
D. melanogaster Feed  10 mM Negative (Wild et al., 1983) Limited validity (low nr of chromosomes, limited reporting) 








D. melanogaster  2000b  and 12 500c  ppm Negative (Foureman et al., 
1994) 
Valid, however, only limited relevance. 
Micronucleus formation CD-1 mice i.p. 540 mg/kg bw (MTD) Negative (McKee et al., 
1987) 
Validity cannot be evaluated. Abstract only; very limited 
information nodata  on PCE/NCE ratio. 
Micronucleus formation CD-1 mice i.p. 0.54 ml/kg bw Negative (O‟Donoghue et 
al., 1988) 
Limited validity. Only one dose level tested, this dose level 
corresponded to the LD20; sample schedule inadequate 
Chromosomal aberration B6C3F1 mice i.p. 125, 250, 500 mg/kg bw Negative NTP-Website Valid. Submitted by Industry in 2009. The standard protocol for in 
vivo CA is not given on the NTP website. However, based on 
Shelby and Witt (1995), animals should have been sampled at 17 
hours and, if negative, also at 36 hours. The data on the NTP 
website are only for bone marrow sampled at 36 hours. It is 
therefore possible that a 17 hours sample was also taken, and 
found to be negative, but the data not posted. Fifty cells per 
animal were scored for CA and no increases in CA were seen. No 
measures of toxicity were recorded, but i.p. dosing should have 
guaranteed systemic exposure. 
DNA binding F344 rats Gavage 500 mg unlabelled 
isophorone / kg bw spiked 
with C14-isophorone  (0.4 
mCi/rat) 
Negative Thier et al., 1990 Limited validity. Submitted by Industry in 2009. No positive 
controls and no untreated controls used. Liver and kidney were 
analysed. 
DNA binding B6C3F1 mice Gavage 500 mg unlabelled 
isophorone / kg bw spiked 
with C14-isophorone (0.08 
mCi/mouse) 
Negative Thier et al., 1990 Limited validity. Submitted by Industry in 2009. No positive 
controls and no untreated controls used. Liver and kidney were 
analysed. 
DNA binding F344 rats (10 males) Gavage 500 mg/kg bw 14C-
isophorone (0.1 mCi/rat) 
Negative Morishita et al., 
1997 
Valid. Preputial glands and kidneys were analysed. 
DNA adducts (32P-
Postlabelling) 
F344 rats (7 males and 
7 females per dose 
group) 
Gavage 0 and 500 mg/kg/day  for 5 
days. 
Negative Morishita et al., 
1997 
Valid. Preputial glands were analysed. 
a: Validity of genotoxicity studies: 
 Valid. 
 Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system). 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
b: Oral administration. 
c: Injection. 
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EU Register name 
JECFA name 







Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
33–3333 µg/plate Negativea (NTP, 2007) 
Mutation Mouse lymphoma 
L5178Y Tk+/- cells 
312.5–5000 µg/ml Negative (NTP, 2007) 
a With and without metabolic activation. 
O
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TABLE 3: SUMMARY OF SAFETY EVALUATIONS 
Table 3.1: Summary of Safety Evaluation of Alicyclic Ketones, Secondary Alcohols and Related Esters (JECFA, 2003a) 
FL-no 
JECFA-no 







Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 




EFSA conclusion on the 









A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 









A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 









A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 









A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
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Table 3.1: Summary of Safety Evaluation of Alicyclic Ketones, Secondary Alcohols and Related Esters (JECFA, 2003a) 
FL-no 
JECFA-no 







Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 




EFSA conclusion on the 








A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 









A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 










A3: Intake below threshold 
4) Evaluated in FGE.211, 
genotoxicity concern could 
be ruled out. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 











A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be 
ruled out. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 










A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 








29 % 68 %
+
O
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Table 3.1: Summary of Safety Evaluation of Alicyclic Ketones, Secondary Alcohols and Related Esters (JECFA, 2003a) 
FL-no 
JECFA-no 







Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 




EFSA conclusion on the 








A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
According to JECFA: Min. 
assay value is "94%" and 
secondary components "2-
Isobutyl cyclohexanone" 
No safety concern at the 
estimated level of intake 









A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be 
ruled out. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
 
No safety concern at the 
estimated level of intake 










A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be 
ruled out. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 










A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be 
ruled out. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 










A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 









A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
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Table 3.1: Summary of Safety Evaluation of Alicyclic Ketones, Secondary Alcohols and Related Esters (JECFA, 2003a) 
FL-no 
JECFA-no 







Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 




EFSA conclusion on the 









A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be 
ruled out. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 










A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 









A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 










A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 












A3: Intake below threshold 
4) Evaluated in FGE.211, 
genotoxicity concern could 
be ruled out. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot.  
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA / FGE.09Rev3) 




Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 










A3: Intake below threshold 








A3: Intake below threshold 








A3: Intake below threshold 








A3: Intake below threshold 








A3: Intake below threshold 
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA / FGE.09Rev3) 




Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 










A3: Intake below threshold 








A3: Intake below threshold 








A3: Intake below threshold 








A3: Intake below threshold 








A3: Intake below threshold 
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA / FGE.09Rev3) 




Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 










A3: Intake below threshold 








A3: Intake below threshold 









A3: Intake below threshold 








A3: Intake below threshold 








B3: Intake below threshold, 
B4: No adequate NOAEL 
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA / FGE.09Rev3) 




Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 











A3: Intake above threshold, 
A4: Not endogenous, A5: 
Adequate NOAEL exists 









A3: Intake below threshold 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot.  
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ABBREVIATIONS 
ATP  Adenosine Tri-Phosphate 
BW  Body weight 
CA  Chromosomal Aberration 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
EPA  United States Environmental Protection Agency  
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GEF  Global Evaluation Factor 
GLP  Good laboratory practise 
ID  Identity 
Ip  Intraperitoneal 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MF  Mutation Frequency 
MLA  Mouse Lymphoma Assay 
MNBN  Micronucleated binucleate cells  
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NCE  Normochromatic erythrocyte 
No  Number 
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NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE  Polychromatic erythrocyte 
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
SLRL  Sex Linked Recessive Lethal Mutations test  
SMART Somatic Mutation And Recombination Test 
UDS  Unscheduled DNA Synthesis 
WHO  World Health Organisation 
 
